Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (11): 673-677.doi: 10.3760/cma.j.cn371439-20201111-00133
• Reviews • Previous Articles Next Articles
Du Chen, Su Siyu, Wang Lige(), Yu Guiping
Received:
2020-11-11
Revised:
2021-05-30
Online:
2021-11-08
Published:
2021-12-14
Contact:
Wang Lige
E-mail:yeke2017@yeah.net
Du Chen, Su Siyu, Wang Lige, Yu Guiping. Advances in neoadjuvant therapy of esophageal cancer involved in organ preservation[J]. Journal of International Oncology, 2021, 48(11): 673-677.
[1] |
Ozawa S, Koyanagi K, Ninomiya Y, et al. Postoperative complications of minimally invasive esophagectomy for esophageal cancer[J]. Ann Gastroenterol Surg, 2020, 4(2):126-134. DOI: 10.1002/ags3.12315.
doi: 10.1002/ags3.12315 pmid: 32258977 |
[2] |
Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—the university of texas md anderson cancer center experience[J]. Cancer, 2017, 123(21):4106-4113. DOI: 10.1002/cncr.30953.
doi: 10.1002/cncr.30953 |
[3] |
Fitzgerald RC. Organ-preserving approaches in oesophageal cancer[J]. Lancet Oncol, 2018, 19(7):858-859. DOI: 10.1016/S1470-2045(18)30291-2.
doi: S1470-2045(18)30291-2 pmid: 29861117 |
[4] |
Bourbonne V, Pradier O, Schick U, et al. Cancer of the oesophagus and lymph nodes management in the neoadjuvant or definitive radiochemotherapy setting[J]. Cancer Radiother, 2019, 23(6-7):682-687. DOI: 10.1016/j.canrad.2019.07.130.
doi: 10.1016/j.canrad.2019.07.130 |
[5] |
de Gouw D, Klarenbeek BR, Driessen M, et al. Detecting pathological complete response in esophageal cancer after neoadjuvant therapy based on imaging techniques: a diagnostic systematic review and meta-analysis[J]. J Thorac Oncol, 2019, 14(7):1156-1171. DOI: 10.1016/j.jtho.2019.04.004.
doi: 10.1016/j.jtho.2019.04.004 |
[6] |
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI: 10.1056/NEJMoa1112088.
doi: 10.1056/NEJMoa1112088 |
[7] |
Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial[J]. JAMA Surg, 2021, 156(8):721-729. DOI: 10.1001/jamasurg.2021.2373.
doi: 10.1001/jamasurg.2021.2373 |
[8] |
Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus[J]. J Clin Oncol, 2005, 23(10):2310-2317. DOI: 10.1200/JCO.2005.00.034.
doi: 10.1200/JCO.2005.00.034 |
[9] |
Mariette C, Dahan L, Mornex F, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer: final analysis of randomized controlled phase Ⅲ trial ffcd 9901[J]. J Clin Oncol, 2014, 32(23):2416-2422. DOI: 10.1200/JCO.2013.53.6532.
doi: 10.1200/JCO.2013.53.6532 |
[10] | Vellayappan BA, Soon YY, Ku GY, et al. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer[J]. Cochrane Database Syst Rev, 2017, 8(8): CD010511. DOI: 10.1002/14651858.CD010511.pub2. |
[11] |
van Rossum PSN, van Hillegersberg R, Meijer GJ, et al. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa[J]. Ann Surg, 2015, 262(2):e83-e84. DOI: 10.1097/SLA.0000000000000671.
doi: 10.1097/SLA.0000000000000671 |
[12] |
Xi M, Yang Y, Zhang L, et al. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes[J]. Ann Surg, 2019, 269(4):663-670. DOI: 10.1097/SLA.0000000000002670.
doi: 10.1097/SLA.0000000000002670 |
[13] |
Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option?[J]. J Clin Oncol, 2015, 33(33):3866-3873. DOI: 10.1200/JCO.2014.59.9092.
doi: 10.1200/JCO.2014.59.9092 |
[14] |
Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer[J]. J Clin Oncol, 2014, 32(30):3400-3405. DOI: 10.1200/JCO.2014.56.7156.
doi: 10.1200/JCO.2014.56.7156 |
[15] |
Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer[J]. Dis Esophagus, 2017, 30(12):1-8. DOI: 10.1093/dote/dox100.
doi: 10.1093/dote/dox086 pmid: 28881884 |
[16] |
Shapiro J, Wijnhoven BP, van Lanschot JJ. Reply to letter: "Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa"[J]. Ann Surg, 2015, 262(2):e84-e85. DOI: 10.1097/SLA.0000000000-000675.
doi: 10.1097/SLA.0000000000000675 |
[17] |
Vollenbrock SE, van Dieren JM, Voncken FEM, et al. Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer[J]. Eur Radiol, 2020, 30(5):2425-2434. DOI: 10.1007/s00330-019-06605-x.
doi: 10.1007/s00330-019-06605-x pmid: 31965258 |
[18] |
Cremonesi M, Garibaldi C, Timmerman R, et al. Interim18F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review[J]. Radiother Oncol, 2017, 125(2):200-212. DOI: 10.1016/j.radonc.2017.09.022.
doi: S0167-8140(17)32589-6 pmid: 29029833 |
[19] |
Yang Z, He B, Zhuang X, et al. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy[J]. J Radiat Res, 2019, 60(4):538-545. DOI: 10.1093/jrr/rrz027.
doi: 10.1093/jrr/rrz027 |
[20] |
Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (presano): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8.
doi: S1470-2045(18)30201-8 pmid: 29861116 |
[21] |
Qin Q, Xu H, Liu J, et al. Does timing of esophagectomy following neoadjuvant chemoradiation affect outcomes? A meta-analysis[J]. Int J Surg, 2018, 59:11-18. DOI: 10.1016/j.ijsu.2018.09.013.
doi: S1743-9191(18)31636-4 pmid: 30261331 |
[22] | Shapiro J, van Hagen P, Lingsma HF, et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer[J]. Ann Surg, 2014, 260(5):813-804; discussion 813-804. DOI: 10.1097/SLA.0000000000000966. |
[23] |
Lu SL, Hsu FM, Tsai CL, et al. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: hypojournal generating for adjuvant treatment[J]. Eur J Surg Oncol, 2019, 45(8):1498-1504. DOI: 10.1016/j.ejso.2019.03.020.
doi: 10.1016/j.ejso.2019.03.020 |
[24] |
Swisher SG, Moughan J, Komaki RU, et al. Final results of NRG Oncology RTOG 0246: an organ-preserving selective resection strategy in esophageal cancer patients treated with definitive chemoradiation[J]. J Thorac Oncol, 2017, 12(2):368-374. DOI: 10.1016/j.jtho.2016.10.002.
doi: 10.1016/j.jtho.2016.10.002 |
[25] |
Ajani JA, Xiao L, Roth JA, et al. A phase Ⅱ randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer[J]. Ann Oncol, 2013, 24(11):2844-2849. DOI: 10.1093/annonc/mdt339.
doi: 10.1093/annonc/mdt339 pmid: 23975663 |
[26] |
Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study[J]. Cancer, 2013, 119(5):939-945. DOI: 10.1002/cncr.27822.
doi: 10.1002/cncr.v119.5 |
[27] |
Cohen C, Tessier W, Gronnier C, et al. Salvage surgery for esophageal cancer: how to improve outcomes?[J]. Ann Surg Oncol, 2018, 25(5):1277-1286. DOI: 10.1245/s10434-018-6365-1.
doi: 10.1245/s10434-018-6365-1 |
[28] |
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J]. Cancer Res, 2014, 74(19):5458-5468. DOI: 10.1158/0008-5472.can-14-1258.
doi: 10.1158/0008-5472.CAN-14-1258 pmid: 25274032 |
[29] |
Nataliya VU, James DM, Daniel MC, et al. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer[J]. J Clin Oncol, 2019, 37(15_suppl):4041-4041. DOI: abs/10.1200/JCO.2019.37.15_suppl.4041
doi: 10.1200/JCO.2019.37.15_suppl.4041 |
[30] |
Jiao R, Luo H, Xu W, et al. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities[J]. Onco Targets Ther, 2019, 12:6023-6032. DOI: 10.2147/OTT.S214579.
doi: 10.2147/OTT |
[31] |
van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. A phase Ⅱ feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: the PERFECT trial[J]. J Clin Oncol, 2019, 37(15_suppl):4045-4045. DOI: abs/10.1200/JCO.2019.37.15_suppl.4045.
doi: 10.1200/JCO.2019.37.15_suppl.4045 |
[32] |
Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1):142. DOI: 10.1186/s12885-018-4034-1.
doi: 10.1186/s12885-018-4034-1 pmid: 29409469 |
[33] |
Borggreve AS, Mook S, Verheij M, et al. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (pride): a multicenter observational study[J]. BMC Cancer, 2018, 18(1):1006. DOI: 10.1186/s12885-018-4892-6.
doi: 10.1186/s12885-018-4892-6 pmid: 30342494 |
[34] |
Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test[J]. Science, 2018, 359(6378):926-930. DOI: 10.1126/science.aar3247.
doi: 10.1126/science.aar3247 |
[35] |
Paterson AL, Lao-Sirieix P, O'Donovan M, et al. Range of pathologies diagnosed using a minimally invasive capsule sponge to evaluate patients with reflux symptoms[J]. Histopathology, 2017, 70(2):203-210. DOI: 10.1111/his.13039.
doi: 10.1111/his.13039 pmid: 27417524 |
[1] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[2] | Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[3] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[4] | Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234. |
[5] | Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42. |
[6] | Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma (2023 Edition) [J]. Journal of International Oncology, 2023, 50(7): 385-397. |
[7] | Xu Fang, Zhu Wentian. Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion [J]. Journal of International Oncology, 2023, 50(5): 304-309. |
[8] | Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81. |
[9] | Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750. |
[10] | Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472. |
[11] | Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian. Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN+ esophageal squamous cell carcinoma patients [J]. Journal of International Oncology, 2022, 49(6): 334-339. |
[12] | Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370. |
[13] | Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong. Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 199-205. |
[14] | Zhou Jianfeng, Wang Tiejun. Targeted therapy and immunotherapy of esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 237-242. |
[15] | Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting. Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis [J]. Journal of International Oncology, 2022, 49(3): 146-150. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||